Abstract
We report a 2.3-year-old girl with complete lack of adenosine deaminase (ADA) activity who presented with severe atopic dermatitis and insulin-dependent diabetes mellitus but only mild recurrent infections. Abnormalities of immune function included profound depletion of CD8+ lymphocytes, hyperimmunoglobulinaemia E, and very low in vitro proliferative response to mitogens. Treatment with polyethylene glycol-conjugated ADA was followed by rapid amelioration of clinical and immunological conditions. The immunological and clinical features of this child suggest that the clinical spectrum of ADA deficiency may be broader than originally supposed.
Similar content being viewed by others
Abbreviations
- ADA:
-
adenosine deaminase
- IDDM:
-
insulin-dependent diabetes mellitus
- PEG-ADA:
-
polyethylene glycol-modified ADA
- PNP:
-
purine nucleoside phospharylase
- SCID:
-
severe combined immunodeficiency
- TCR:
-
T-cell antigen receptor
References
Ammann AJ, Cowan MS, Martin DW, Wara DW (1983) Dipyridamole and intravenous deoxycytidine therapy in a patient with adenosine deaminase deficiency. Birth Defects 19:117–120
Bellgrau D, Lagarde AC (1990) Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implication for generation of an autoimmune T-cell repertoire. Proc Natl Acad Sci USA 87:313–317
Borst J, Van Dongen JJM, De Vries E, Comans-Bitter WM, Van Tol MJD, Vossen JM, Kurrle R (1990) BMA031, a monoclonal antibody specifically suited to identify the T cell receptor αβ/CD3 complex on viable human T lymphocytes in normal and disease states. Hum Immunol 29:175–188
Carbonari M, Cherchi M, Paganelli R (1990) Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia. N Engl J Med 322:73–76
Cederbaum SD, Kaitila L, Rimoin DL, Stiehm ER (1976) The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency. J Pediatr 89:737–742
Cowan MS, Smith W, Ammann AJ (1989) Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency. Clin Immunol Immunopathol 53:59–67
Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, Bordingnon C (1991) An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251:1363–1366
Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, Porta F, Griscelli C, Goldman SF, Levinsky R, Vossen J (1990) European experience of bone marrow transplantation for severe combined immunodeficiency. Lancet II:850–854
Geffner ME, Stiehn ER, Stephure D, Cowan MJ (1986) Probable autoimmune thyroid disease and combined immunodeficiency disease. Am J Dis Child 140:1194–1196
Gene therapy begins [News] (1990) Science 294: 1372
Georgiou HM, Lagarde AC, Bellgrau D (1988) T cell dysfunction in the diabetes-prone BB rat. A role for thymic migrants that are not T cell precursors. J Exp Med 167:132–148
Giblett ER, Anderson JE, Cohen H, Pollara B, Meuwissen HJ (1972) Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet II:1067–1069
Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, Abuchowski A (1987) Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA). N Engl J Med 316:589–596
Hirschhorn ER (1977) Defects of purine metabolism in immunodeficiency diseases. Progr Clin Immunol 3:67–83
Hirschhorn R (1983) Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase: overview, genetic heterogeneity and therapy. In: Wedgwood RJ, Rosen FS, Paul NW (eds) Primary immunodeficiency diseases. Alan R Liss, New York, pp 73–81
Hirschhorn R (1986) Inherited enzyme deficiencies and immunodeficiency: Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) deficiencies. Clin Immunol Immunopathol 40:157–165
Hirschhorn R, Ellenbogen A (1987) Genetic heterogeneity in adenosine deaminase (ADA) deficiency: five different mutations in five new patients with partial ADA deficiency. Am J Hum Genet 38:13–25
Hirschhorn R, Papageorgiou PS, Kesariwala HH, Taft LT (1980) Amelioration of neurologic abnormalities after “enzyme replacement” in adenosine deaminase deficiency. N Engl J Med 303:377–380
Hirschhorn R, Tzall S, Ellenbogen A (1990) Hot spot point mutations in adenosine deaminase deficiency. Proc Natl Acad Sci USA 87:6171–6175
Jenkins T, Rabson AR, Nurse GT, Lane AB, Hopkinson DA (1976) Deficiency of adenosine deaminase not associated with severe combined immunodeficiency. J Pediatr 89:732–736
Kredich NM, Hershfield MS (1989) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease. Mc Gray Hill, New York, pp. 1045–1075
Kurlandsky LE (1988) Hyperimmunoglobulinemia E in a child with partial adenosine deaminase (ADA) deficiency. Pediatr Res 23:356A
Levy Y, Fernandez Mejia C, Hershfield MS, Polmar SH, Sudiery D, Berger M, Sorensen RU (1988) Adenosine deaminase (ADA) deficiency in a patient with late onset of recurrent infections: response to polyethylene glycol (PEG) modified ADA treatment. Pediatr Res 23:356A
Linch DC, Levinsky RJ, Rodeck CH, Mac Lennan KA, Simmonds HA (1984) Prenatal diagnosis of three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of gestation in fetuses with adenosine deaminase deficiency. Clin Exp Immunol 56:222–228
Markert ML, Norby-Slycord C, Ward FE (1989) A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am J Hum Genet 45:354–361
Maruta K, Treichel U, Kolb-Bachofen V, Kolb H (1989) Prospective analysis of eosinophilia in spontaneously diabetic BB rats: correlation with islet inflammation but not with diabetes development. Diabetes Res 11:173–176
Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA (1987) Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency. Clin Exp Immunol 70:491–499
Ratech H, Greco MA, Gallo G, Rimoin DI, Kamino H, Hirschhorn R (1985) Pathologic findings in adenosine-deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations. Am J Pathol 120:157–168
Ratech H, Hirschhorn R, Greco MA (1989) Pathological findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol 135:1145–1156
Rossini AA, Mordes JP, Greiner DL (1990) The pathogenesis of autoimmune diabetes mellitus. Curr Opin Immunol 2:598–603
Simmonds HA, Fairbanks LD, Morris GS, Webster DR, Harley EH (1988) Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine and pyrimidine metabolism. Clin Chim Acta 171:197–210
Wilson DK, Rudolph FB, Quiocho FA (1991) Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 252:1278–1284
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Notarangelo, L.D., Stoppoloni, G., Toraldo, R. et al. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur J Pediatr 151, 811–814 (1992). https://doi.org/10.1007/BF01957930
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957930